Start Creating
Convert Image
Features
Pricing
Blog

SciDraw

AI-powered scientific illustration platform for researchers and PhD students. Create publication-ready TOC graphics, journal covers, conference posters, and research figures in minutes. No design skills required.

Email Stripe Climate

Stripe Climate Contribution

Product

Features
Pricing
Gallery

Blog

Product
Tutorials
Changelog

Legal

Cookie Policy
Privacy Policy
Terms of Service

© 2026 SciDraw All Rights Reserved.

Back to Gallery

Ultraviolet mutagenesis of fungal spores, performed in a petri dish.

Biomedical

Prompt Description

Ultraviolet mutagenesis of fungal spores, performed in a petri dish.

Related Illustrations

A schematic diagram comparing Separate Hydrolysis and Fermentation (SHF) and Simultaneous Saccharification and Fermentation (SSF). The SHF section shows two large fermentation tanks, labeled separately as 'Saccharification Tank' and 'Fermentation Tank'. The saccharification tank contains a diagram illustrating 'cellulase' (represented by a cellulase icon) cutting 'cellulose chains', producing a large amount of 'glucose' and 'cellobiose' accumulating in the tank. An arrow leads to the text annotation: 'Product accumulation → Strong feedback inhibition → Decreased enzyme efficiency'. The SSF section shows one fermentation tank, with a dynamic diagram inside illustrating 'cellulase' cutting cellulose. The 'sugar molecules' produced are immediately 'consumed' by the adjacent 'yeast cells' (connected by arrows). A nearby arrow points out and is labeled: 'Simultaneous saccharification and fermentation → Immediate sugar consumption → Product concentration close to zero → Inhibition relieved.'

A schematic diagram comparing Separate Hydrolysis and Fermen...

Firstly, recombinant insulin, produced through industrialized fermentation and standardized purification, ensures high purity and batch-to-batch consistency, which is the foundation of biopharmaceutical quality control. Secondly, as a human-derived sequence, recombinant formulations exhibit significantly reduced immunogenicity, leading to better patient tolerance. Thirdly, clinical PK/PD data indicate that recombinant formulations are at least equivalent to traditional semi-synthetic insulin in terms of hypoglycemic effect and safety, and they provide a molecular modification platform for rapid-acting or long-acting analogs, meeting the needs of individualized treatment. Finally, with continuous optimization of fermentation and purification processes, recombinant production possesses the advantages of scalability and controllable costs, enabling long-term stable supply.

Firstly, recombinant insulin, produced through industrialize...

Lactic acid exerts diverse physiological functions by activating three main signaling pathways via the GPR81 receptor. In the cAMP-AC pathway, upon binding to GPR81, lactic acid inhibits adenylyl cyclase through Gi protein, reducing cAMP levels and PKA activity. This process inhibits lipolysis and promotes triglyceride storage in adipose tissue, reduces CREB phosphorylation and increases intramuscular fat accumulation in muscle tissue, and decreases neuronal excitability to trigger an energy-saving mode in brain tissue. In the ERK1/2 pathway, the lactic acid-GPR81 signal activates the Ras-Raf-MEK-ERK cascade through the Giβγ subunit, promoting skeletal muscle hypertrophy and enhanced mitochondrial function, increasing ATP production and oxidative phosphorylation capacity, while also regulating bone metabolism by promoting osteoblast differentiation and inhibiting osteoclasts. In the β-arrestin pathway, lactic acid activates GPR81 and recruits β-arrestin2, which inhibits the TLR4/NLRP3 inflammasome to exert anti-inflammatory effects and reduce IL-1β production, and promotes STAT1/2 dephosphorylation to participate in tumor immune escape. These three pathways collectively constitute the GPR81-mediated lactic acid signaling network, regulating various physiological processes such as metabolic balance, exercise adaptation, and immune responses.

Lactic acid exerts diverse physiological functions by activa...

Limitations and Challenges of Recombinant Human Insulin: 1. Limitations in Delivery Methods - Primarily subcutaneous injection, affecting patient compliance and quality of life. 2. Accessibility and Cost Issues - Supply and cost remain challenges in low-resource regions. 3. Limitations of Expression Systems - E. coli cannot perform eukaryotic glycosylation, limiting certain modified drugs. 4. Limitations of Pharmacokinetic Properties - Natural insulin has a short half-life, requiring multiple administrations, necessitating alternatives or analogs for improvement.

Limitations and Challenges of Recombinant Human Insulin: 1. ...

Ultraviolet mutagenesis of fungal spores, performed in a ... | SciDraw Gallery